Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer's disease at the prodromal stage
Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer's disease at the prodromal stage
复制标题
DOI：
10.1136/jnnp-2017-316385
复制
发表时间：
2018-05-01
影响因子：
11
通讯作者：
Blanc, Frederic
中科院分区：
文献类型：
--
作者：
Bousiges, Olivier;Bombois, Stephanie;Blanc, Frederic
背景路易体痴呆（DLB）和阿尔茨海默病（AD）的鉴别诊断并不简单，尤其是在疾病的早期阶段。我们比较了AD的生物标志物（磷酸-Tau 181，总-Tau，A β 42和A β 40）在DLB和AD患者的脑脊液（CSF），特别是集中在前驱stage.Methods共收集了1221 CSF在不同的记忆中心（ePLM网络）在法国和回顾性分析。样品获自前驱DLB（pro-DLB; n= 57）、DLB痴呆（DLB-d; n= 154）、前驱AD（pro-AD; n= 132）和AD痴呆（n= 783）患者以及对照受试者（CS; n= 95）。这些中心使用相同的诊断程序和标准，以评估patient.Results在患者与前DLB，CSF A β 42水平出现比患者在痴呆阶段（DLB-d）（Ppro-DLB; PDLB-d）的干扰少得多。平均而言，DLB患者（pro-DLB和DLB-d）的A β 40水平远低于pro-AD患者（P< 0.001
Background Differential diagnosis between dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) is not straightforward, especially in the early stages of disease. We compared AD biomarkers (phospho-Tau 181, total-Tau, A beta 42 and A beta 40) in cerebrospinal fluid (CSF) of patients with DLB and AD, focusing especially on the prodromal stage.Methods A total of 1221 CSF were collected in different memory centres (ePLM network) in France and analysed retrospectively. Samples were obtained from patients with prodromal DLB (pro-DLB; n= 57), DLB dementia (DLB-d; n= 154), prodromal AD (pro-AD; n= 132) and AD dementia (n= 783), and control subjects (CS; n= 95). These centres use the same diagnostic procedure and criteria to evaluate the patients.Results In patients with pro-DLB, CSF A beta 42 levels appeared much less disrupted than in patients at the demented stage (DLB-d) (Ppro-DLB; PDLB-d). On average, A beta 40 levels in patients with DLB (pro-DLB and DLB-d) were much below those in patients with pro-AD (P< 0.001 DLB groups